A Phase 3 interventional study of Quetiapine XR and Lithium carbonate in Major Depressive Disorder and Treatment Resistant Depression, sponsored by AstraZeneca. Completed at 106 sites in 13 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2012-05-23.
Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 32 studies testing quetiapine in Depressive Disorder, Major — 1 open to participants now, 2 under way, none of them phase 3. quetiapine · Depressive Disorder, Major.
Among the 32 studies testing quetiapine in Depressive Disorder, Major, this one is the 4th largest by enrollment of the 31 interventional ones that give a count, is one of 5 that started in 2008, is one of 11 in phase 3, and was the 12th registered.
3,050 studies on the registry are indexed under Depressive Disorder, Major; 594 are open to participants now.
Browse Depressive Disorder, Major studies →1 of the 32 studies testing quetiapine in Depressive Disorder, Major is open now, in 1 country. Recruiting first, the newest first:
First Affiliated Hospital of Zhejiang University · Sites in China
Ages 16–65 · Healthy volunteers
By country, each count listing its studies:
quetiapine: first FDA approval 1997 (SEROQUEL). What it is approved for, and how studies give it, is on its page →
Of the 415 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 295 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
32 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 5 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 688 is above the median of 80 across 2,536 interventional studies indexed under Depressive Disorder, Major.
Median enrollment 60 across the 31 interventional studies. Of the 27 that completed or were terminated, 9 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 32 have an industry lead sponsor. The 10 most frequent:
AstraZeneca is the lead sponsor of 3,504 studies on the registry; 274 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
35 studies in Depressive Disorder, Major by AstraZeneca: none open now, none under way, none of them phase 3. Of 35 finished, 13 (37%) have results posted.
Among the 35 studies in Depressive Disorder, Major by AstraZeneca, this one is the 5th largest by enrollment of the 23 interventional ones that give a count, is one of 4 that started in 2008, is one of 14 in phase 3, and was the 13th registered.
AstraZeneca’s Depressive Disorder, Major studies by the year they started, since 2005.
1 of the studies testing quetiapine in Depressive Disorder, Major that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05480150First Affiliated Hospital of Zhejiang UniversityChinese Longitudinal and Systematic Study of Bioplar Disorder | 2026-12-31 |
Add it to your calendar (.ics) → With an account.
Among the 32 studies testing quetiapine in Depressive Disorder, Major, from their registry updates:
Among AstraZeneca’s 35 in Depressive Disorder, Major:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary objective of the study is to evaluate the efficacy of Quetiapine extended release (XR) in combination with an selective serotonin reuptake inhibitor (SSRI) or Venlafaxine versus Lithium in combination with an selective serotonin reuptake inhibitor or Venlafaxine versus Quetiapine extended release monotherapy in subjects with treatment resistant depression as assessed by the changes from randomisation to week 6 in the Montgomery-Åsberg Depression Rating Scale (MADRS) total score. As an independent objective, the primary objective will also be evaluated in two subgroups of patients: (1) patients who were resistant to two previous antidepressant therapies and (2) in the subgroup of patients with one previous failure.
The secondary objectives of the study are to compare the effects of the three different treatment regimen as assessed by the following variables and, if applicable, by their changes from randomisation to week 6 (end of study). Additionally the time of onset of therapeutic effect will be assessed by evaluating efficacy data after the first four days (Day 4) of treatment as well as after the first week of treatment (Day 8). These analyses will also be performed in the subgroups of patients with 2 failed previous antidepressants and patients with 1 failure.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Selective serotonin reuptake inhibitors (SSRI) or Venlafaxine from previous therapy + add-on treatment with quetiapine XR, 300mg tablet once daily (od). From previous anti-depressant treatment 64% of the patients had SSRI and 35% had Venlafaxine at baseline.
Drug: Quetiapine XR · Drug: SSRI/Venlafaxine
Selective serotonin reuptake inhibitors (SSRI) or venlafaxine from previous therapy + add-on treatment with lithium, approximately 900mg tablet once daily (od). From previous anti-depressant treatment 67% of the patients had SSRI and 33% had Venlafaxine at baseline.
Drug: Lithium carbonate · Drug: SSRI/Venlafaxine
Switch from previous treatment with SSRI or venlafaxine to quetiapine XR monotherapy, 300mg tablet once daily (od)
Drug: Quetiapine XR
300 mg once daily (od)
Also known as: Seroquel XR
900 mg once daily (od)
Also known as: Quilonum Retard
Drug page: Venlafaxine
SSRI - doses within label, Venlafaxine dose up to 225 mg/day
Change in Depressive Symptoms Between Randomisation and Week 6 Measured by Change in Montgomery Asberg Depression Rating Scale (MADRS) Total Score (Per Protocol Analysis Set)
Change in LS mean total Montgomery Asberg Depression Rating Scale (MADRS) score from randomisation to end-of-treatment (week 6) (Scale 0-60), lower score indicates a better health status.
Time frame: 6 weeks treatment
Change in Depressive Symptoms Between Randomisation and Week 6 Measured by Change in Montgomery Asberg Depression Rating Scale (MADRS) Total Score (Modified Intention to Treat Analysis Set)
Change in LS mean total Montgomery Asberg Depression Rating Scale (MADRS) score from randomisation to end-of-treatment (week 6) (Scale 0-60), lower score indicates a better health status.
Time frame: 6 weeks of treatment
Depression Remission; Montgomery-Asberg Depression Rating Scale MADRS ≤10, All Patients
Number of patients in remission, with total Montgomery Asberg Depression Rating Scale (MADRS) score ≤10. MADRS scale has range from 0 to 60, where the lower score indicates the better health status.
Time frame: 6 weeks of treatment
Depression Remission; Montgomery-Asberg Depression Rating Scale (MADRS) ≤10, Patients With One Previous Treatment Failure
Number of patients in remission with one previous treatment failure and with total Montgomery Asberg Depression Rating Scale (MADRS) score ≤10. MADRS scale has range from 0 to 60, where the lower score indicates the better health status.
Time frame: 6 weeks of treatment
Depression Remission; Montgomery-Asberg Depression Rating Scale (MADRS) ≤10, Patients With Two Previous Treatment Failure
Number of patients in remission with two previous treatment failure and with total Montgomery Asberg Depression Rating Scale (MADRS) score ≤10. MADRS scale has range from 0 to 60, where the lower score indicates the better health status.
Time frame: 6 weeks of treatment
Depression Remission; Montgomery-Asberg Depression Rating Scale (MADRS) ≤8
Number of patients in remission with total Montgomery Asberg Depression Rating Scale (MADRS) score ≤8. MADRS scale has range from 0 to 60, where the lower score indicates the better health status.
Time frame: 6 weeks of treatment
Depression Remission; Montgomery-Asberg Depression Rating Scale (MADRS) ≤12
Number of patients in remission with total Montgomery Asberg Depression Rating Scale (MADRS) score ≤12. MADRS scale has range from 0 to 60, where the lower score indicates the better health status.
Time frame: 6 weeks of treatment
Response Rate; Montgomery-Asberg Depression Rating Scale (MADRS) Score Reduced ≥ 50%, All Patients
Response rate at end of study measured as number of patients with Montgomery Asberg Depression Rating Scale (MADRS) with total score reduction ≥ 50% compared to baseline, the higher number of patients the better
Time frame: 6 week of treatments
Response Rate; Montgomery-Asberg Depression Rating Scale (MADRS) Score Reduced ≥ 50%, Patients With One Previous Treatment Failure
Response rate at end of study measured as number of patients with Montgomery Asberg Depression Rating Scale (MADRS) with total score reduction ≥ 50% compared to baseline, the higher number of patients the better
Time frame: 6 weeks of treatment
Response Rate; Montgomery-Asberg Depression Rating Scale (MADRS) Score Reduced ≥ 50%, Patients With Two Previous Treatment Failure
Response rate at end of study measured as number of patients with Montgomery Asberg Depression Rating Scale (MADRS) with total score reduction ≥ 50% compared to baseline, the higher number of patients the better
Time frame: 6 weeks of treatment
Responder: Clinical Global Impression Improvement (CGI-I) Item 2, All Patients
Change in global improvement measured by Clinical Global Impression Improvement (CGI-I). Scale from 1-4, where lower value shows a larger improvement.
Time frame: 6 weeks of treatment
Responder: Clinical Global Impression Improvement (CGI)-I Item 2, Patients With One Previous Treatment Failure
Change in global improvement measured by Clinical Global Impression Improvement (CGI-I). Scale from 1-4, where a lower value shows a larger improvement.
Time frame: 6 weeks of treatment
Responder: Clinical Global Impression Improvement (CGI-I) Item 2, Patients With Two Previous Treatment Failure
Change in global improvement measured by Clinical Global Impression Improvement (CGI-I). Scale from 1-4, where a lower value shows a larger improvement.
Time frame: 6 weeks of treatment
Change in Clinical Global Impression Scale (CGI-S), All Patients
Change in severity of illness measured by Clinical Global Impression Scale (CGI-S). Scale form 1-7, where a lower value shows a larger improvement.
Time frame: 6 weeks of treatment
Change in Clinical Global Impression Scale (CGI-S), Patients With One Previous Treatment Failure
Change in severity of illness measured by Clinical Global Impression Scale (CGI-S). Scale from 1-7, where a lower value shows a larger improvement.
Time frame: 6 weeks of treatment
Change in Clinical Global Impression Scale (CGI-S), Patients With Two Previous Treatment Failure
Change in severity of illness measured by Clinical Global Impression Scale (CGI-S). Scale from 1-7, where a lower value shows a larger improvement.
Time frame: 6 weeks of treatment
Change in Beck Depression Inventory (BDI)
Self-rating assessment of depressive symptoms using Beck Depression Inventory (BDI). Scale from 0-63, where a lower value shows a larger improvement.
Time frame: 6 weeks of treatment
Change in Pain, Measured by Visual Analog Scale (VAS)
Self-rating assessment of pain using a visual analogue scale (VAS). Scale from 0-100, where a lower value shows a larger improvement.
Time frame: 6 weeks of treatment
Change in Anxiety Measured by Visual Analog Scale (VAS)
Self-rating assessment of anxiety using a visual analogue scale (VAS). Scale from 0-100, where a lower value shows a larger improvement.
Time frame: 6 weeks of treatment
Change in Anxiety Measured by State-Trait Anxiety Inventory (STAI), State Anxiety Inventory
Self-rating assessment of anxiety measured by STAI, state anxiety inventory (Scale 20-80, where a lower value shows a larger improvement)
Time frame: 6 weeks of treatment
Change in Anxiety Measured by STAI, Trait Anxiety Inventory
Self-rating assessment of anxiety measured by State-Trait Anxiety Inventory (STAI), trait anxiety inventory (Scale 20-80, where a lower value shows a larger improvement)
Time frame: 6 weeks of treatment
Change in Sleep Quality Measured by Montgomery Asberg Depression Rating Scale (MADRS), Item 4
Sleeping quality measured by Montgomery-Asberg Depression Rating Scale (MADRS) item 4 (reduced sleep) (Scale 0-6, where a lower value shows a larger improvement)
Time frame: 6 weeks of treatment
Change in Sleep Quality Measured by Pittsburgh Sleep Quality Index (PSQI)
Self-rated sleeping quality measured by PSQI (Scale 0-21, subscales 0-3, 18 questions, where a lower value shows a larger improvement)
Time frame: 6 weeks of treatment
Change in Quality of Life Measured by Short-form Health Survey (SF-36), Mental Component
Self rating assessment of quality in life using SF-36, mental component (Scale 0-100, where a higher value shows a larger improvement)
Time frame: 6 weeks of treatment
Change in Quality of Life Measured by Short-form Health Survey (SF-36), Physical Component
Self rating assessment of quality in life using SF-36, physical component (Scale 0-100, where a higher value shows a larger improvement)
Time frame: 6 weeks of treatment
Change in Quality of Life Measured by Health Questionnaire EQ-5D as Utility
Self rating assessment of quality in life using EQ-5D utility (Scale 0-100, where a higher value shows a larger improvement)
Time frame: 6 weeks of treatment
Change in Work Productivity and Activity Impairment: General Health (WPAI:GH)
Self rating assessment of working productivity using WPAI:GH (Scale 0 to number of hours worked during a week multiplied with the salary in Euro, a lower value shows a larger improvement)
Time frame: 6 weeks of treatment
Change in Clinical Global Impression (CGI) Item 4 Efficacy and Safety Combined, All Patients
The physician has evaluated the therapeutic effect and the side effect combined at end of study. Patients with a 'marked/moderate' therapeutic effect and 'None/Do Not Significantly Interfere' side effect has been added. The higher values show more patients with a treatment effect without any side-effect. The range is from 0 patients to the maximum number of patients in the treatment arm (225, 229 or 221).
Time frame: 6 weeks of treatment
Change in Clinical Global Impression (CGI) Item 4 Efficacy and Safety Combined, Patients With One Previous Treatment Failure
The physician has evaluated the therapeutic effect and the side effect combined at end of study. Patients with a 'marked/moderate' therapeutic effect and 'None/Do Not Significantly Interfere' side effect has been added. The higher values show more patients with a treatment effect without any side-effect. The range is from 0 patients to the maximum number of patients in the treatment arm.
Time frame: 6 weeks of treatment
Change in Clinical Global Impression (CGI) Item 4 Efficacy and Safety Combined, Patients With Two Previous Treatment Failures
The physician has evaluated the therapeutic effect and the side effect combined at end of study. Patients with a 'marked/moderate' therapeutic effect and 'None/Do Not Significantly Interfere' side effect has been added. The higher values show more patients with a treatment effect without any side-effect. The range is from 0 patients to the maximum number of patients in the treatment arm.
Time frame: 6 week of treatments
This was a 3 arm, open-label randomised, rater blinded, parallel group study comparing quetiapine XR monotherapy and augmentation with lithium augmentation in patients with treatment resistant depression, Recruitment period 6 November 2008 to 19 June 2009
| Milestone | Quetiapine XR Mono | Add-on Quetiapine XR | Add-on Lithium |
|---|---|---|---|
| Started | 228 | 231 | 229 |
| Completed | 179 | 196 | 182 |
| Not completed | 49 | 35 | 47 |
| Withdrew: Adverse event | 28 | 23 | 18 |
| Withdrew: Lost to follow-up | 1 | 1 | 4 |
| Withdrew: Withdrawal by subject | 9 | 6 | 17 |
| Withdrew: Eligibility criteria not fulfilled | 2 | 5 | 1 |
| Withdrew: Severe non-compliance to the protocol | 3 | 0 | 0 |
| Withdrew: Safety reasons | 0 | 0 | 2 |
| Withdrew: Other | 6 | 0 | 5 |
Change in LS mean total Montgomery Asberg Depression Rating Scale (MADRS) score from randomisation to end-of-treatment (week 6) (Scale 0-60), lower score indicates a better health status.
| scores on a scale | Quetiapine XR Mono | Add-on Quetiapine XR | Add-on Lithium |
|---|---|---|---|
| Change in Depressive Symptoms Between Randomisation and Week 6 Measured by Change in Montgomery Asberg Depression Rating Scale (MADRS) Total Score (Per Protocol Analysis Set) | -16.2 ± 0.843 | -17.2 ± 0.826 | -14.9 ± 0.97 |
Change in LS mean total Montgomery Asberg Depression Rating Scale (MADRS) score from randomisation to end-of-treatment (week 6) (Scale 0-60), lower score indicates a better health status.
| scores on a scale | Quetiapine XR Mono | Add-on Quetiapine XR | Add-on Lithium |
|---|---|---|---|
| Change in Depressive Symptoms Between Randomisation and Week 6 Measured by Change in Montgomery Asberg Depression Rating Scale (MADRS) Total Score (Modified Intention to Treat Analysis Set) | -13.9 ± 0.806 | -15.1 ± 0.797 | -13.3 ± 0.801 |
Number of patients in remission, with total Montgomery Asberg Depression Rating Scale (MADRS) score ≤10. MADRS scale has range from 0 to 60, where the lower score indicates the better health status.
| Participants | Quetiapine XR Mono | Add-on Quetiapine XR | Add-on Lithium |
|---|---|---|---|
| Depression Remission; Montgomery-Asberg Depression Rating Scale MADRS ≤10, All Patients | 53 | 73 | 60 |
Number of patients in remission with one previous treatment failure and with total Montgomery Asberg Depression Rating Scale (MADRS) score ≤10. MADRS scale has range from 0 to 60, where the lower score indicates the better health status.
| Participants | Quetiapine XR Mono | Add-on Quetiapine XR | Add-on Lithium |
|---|---|---|---|
| Depression Remission; Montgomery-Asberg Depression Rating Scale (MADRS) ≤10, Patients With One Previous Treatment Failure | 22 | 42 | 31 |
Number of patients in remission with two previous treatment failure and with total Montgomery Asberg Depression Rating Scale (MADRS) score ≤10. MADRS scale has range from 0 to 60, where the lower score indicates the better health status.
| Participants | Quetiapine XR Mono | Add-on Quetiapine XR | Add-on Lithium |
|---|---|---|---|
| Depression Remission; Montgomery-Asberg Depression Rating Scale (MADRS) ≤10, Patients With Two Previous Treatment Failure | 31 | 31 | 29 |
Number of patients in remission with total Montgomery Asberg Depression Rating Scale (MADRS) score ≤8. MADRS scale has range from 0 to 60, where the lower score indicates the better health status.
| Participants | Quetiapine XR Mono | Add-on Quetiapine XR | Add-on Lithium |
|---|---|---|---|
| Depression Remission; Montgomery-Asberg Depression Rating Scale (MADRS) ≤8 | 35 | 58 | 45 |
Number of patients in remission with total Montgomery Asberg Depression Rating Scale (MADRS) score ≤12. MADRS scale has range from 0 to 60, where the lower score indicates the better health status.
| Participants | Quetiapine XR Mono | Add-on Quetiapine XR | Add-on Lithium |
|---|---|---|---|
| Depression Remission; Montgomery-Asberg Depression Rating Scale (MADRS) ≤12 | 67 | 89 | 73 |
Response rate at end of study measured as number of patients with Montgomery Asberg Depression Rating Scale (MADRS) with total score reduction ≥ 50% compared to baseline, the higher number of patients the better
| Participants | Quetiapine XR Mono | Add-on Quetiapine XR | Add-on Lithium |
|---|---|---|---|
| Response Rate; Montgomery-Asberg Depression Rating Scale (MADRS) Score Reduced ≥ 50%, All Patients | 114 | 120 | 102 |
Response rate at end of study measured as number of patients with Montgomery Asberg Depression Rating Scale (MADRS) with total score reduction ≥ 50% compared to baseline, the higher number of patients the better
| Participants | Quetiapine XR Mono | Add-on Quetiapine XR | Add-on Lithium |
|---|---|---|---|
| Response Rate; Montgomery-Asberg Depression Rating Scale (MADRS) Score Reduced ≥ 50%, Patients With One Previous Treatment Failure | 54 | 65 | 53 |
Response rate at end of study measured as number of patients with Montgomery Asberg Depression Rating Scale (MADRS) with total score reduction ≥ 50% compared to baseline, the higher number of patients the better
| Participants | Quetiapine XR Mono | Add-on Quetiapine XR | Add-on Lithium |
|---|---|---|---|
| Response Rate; Montgomery-Asberg Depression Rating Scale (MADRS) Score Reduced ≥ 50%, Patients With Two Previous Treatment Failure | 60 | 55 | 49 |
Change in global improvement measured by Clinical Global Impression Improvement (CGI-I). Scale from 1-4, where lower value shows a larger improvement.
| scores on a scale | Quetiapine XR Mono | Add-on Quetiapine XR | Add-on Lithium |
|---|---|---|---|
| Responder: Clinical Global Impression Improvement (CGI-I) Item 2, All Patients | -1.54 ± 1.24 | -1.85 ± 1.34 | -1.58 ± 1.32 |
Change in global improvement measured by Clinical Global Impression Improvement (CGI-I). Scale from 1-4, where a lower value shows a larger improvement.
| scores on a scale | Quetiapine XR Mono | Add-on Quetiapine XR | Add-on Lithium |
|---|---|---|---|
| Responder: Clinical Global Impression Improvement (CGI)-I Item 2, Patients With One Previous Treatment Failure | -1.42 ± 1.17 | -1.91 ± 1.31 | -1.62 ± 1.27 |
Change in global improvement measured by Clinical Global Impression Improvement (CGI-I). Scale from 1-4, where a lower value shows a larger improvement.
| scores on a scale | Quetiapine XR Mono | Add-on Quetiapine XR | Add-on Lithium |
|---|---|---|---|
| Responder: Clinical Global Impression Improvement (CGI-I) Item 2, Patients With Two Previous Treatment Failure | -1.67 ± 1.30 | -1.79 ± 1.36 | -1.54 ± 1.38 |
Change in severity of illness measured by Clinical Global Impression Scale (CGI-S). Scale form 1-7, where a lower value shows a larger improvement.
| scores on a scale | Quetiapine XR Mono | Add-on Quetiapine XR | Add-on Lithium |
|---|---|---|---|
| Change in Clinical Global Impression Scale (CGI-S), All Patients | -1.43 ± 0.101 | -1.65 ± 0.099 | -1.49 ± 0.1 |
Change in severity of illness measured by Clinical Global Impression Scale (CGI-S). Scale from 1-7, where a lower value shows a larger improvement.
| scores on a scale | Quetiapine XR Mono | Add-on Quetiapine XR | Add-on Lithium |
|---|---|---|---|
| Change in Clinical Global Impression Scale (CGI-S), Patients With One Previous Treatment Failure | -1.45 ± 0.133 | -1.82 ± 0.13 | -1.59 ± 0.13 |
Change in severity of illness measured by Clinical Global Impression Scale (CGI-S). Scale from 1-7, where a lower value shows a larger improvement.
| scores on a scale | Quetiapine XR Mono | Add-on Quetiapine XR | Add-on Lithium |
|---|---|---|---|
| Change in Clinical Global Impression Scale (CGI-S), Patients With Two Previous Treatment Failure | -1.52 ± 0.133 | -1.55 ± 0.131 | -1.45 ± 0.135 |
Self-rating assessment of depressive symptoms using Beck Depression Inventory (BDI). Scale from 0-63, where a lower value shows a larger improvement.
| scores on a scale | Quetiapine XR Mono | Add-on Quetiapine XR | Add-on Lithium |
|---|---|---|---|
| Change in Beck Depression Inventory (BDI) | -11.7 ± 0.926 | -13.5 ± 0.921 | -12.2 ± 0.922 |
Self-rating assessment of pain using a visual analogue scale (VAS). Scale from 0-100, where a lower value shows a larger improvement.
| scores on a scale | Quetiapine XR Mono | Add-on Quetiapine XR | Add-on Lithium |
|---|---|---|---|
| Change in Pain, Measured by Visual Analog Scale (VAS) | -9.47 ± 1.695 | -8.03 ± 1.681 | -8.3 ± 1.682 |
Self-rating assessment of anxiety using a visual analogue scale (VAS). Scale from 0-100, where a lower value shows a larger improvement.
| scores on a scale | Quetiapine XR Mono | Add-on Quetiapine XR | Add-on Lithium |
|---|---|---|---|
| Change in Anxiety Measured by Visual Analog Scale (VAS) | -21.2 ± 1.972 | -23.4 ± 1.947 | -20.6 ± 1.952 |
Self-rating assessment of anxiety measured by STAI, state anxiety inventory (Scale 20-80, where a lower value shows a larger improvement)
| Scores on a scale | Quetiapine XR Mono | Add-on Quetiapine XR | Add-on Lithium |
|---|---|---|---|
| Change in Anxiety Measured by State-Trait Anxiety Inventory (STAI), State Anxiety Inventory | -0.62 ± 0.347 | 0.014 ± 0.344 | -0.87 ± 0.35 |
Self-rating assessment of anxiety measured by State-Trait Anxiety Inventory (STAI), trait anxiety inventory (Scale 20-80, where a lower value shows a larger improvement)
| Scores on a scale | Quetiapine XR Mono | Add-on Quetiapine XR | Add-on Lithium |
|---|---|---|---|
| Change in Anxiety Measured by STAI, Trait Anxiety Inventory | -1.01 ± 0.331 | -1.36 ± 0.328 | -1.39 ± 0.331 |
Sleeping quality measured by Montgomery-Asberg Depression Rating Scale (MADRS) item 4 (reduced sleep) (Scale 0-6, where a lower value shows a larger improvement)
| MADRS item 4 score | Quetiapine XR Mono | Add-on Quetiapine XR | Add-on Lithium |
|---|---|---|---|
| Change in Sleep Quality Measured by Montgomery Asberg Depression Rating Scale (MADRS), Item 4 | -2.2 ± 0.108 | -2.4 ± 0.107 | -1.63 ± 0.108 |
Self-rated sleeping quality measured by PSQI (Scale 0-21, subscales 0-3, 18 questions, where a lower value shows a larger improvement)
| Scores on a scale | Quetiapine XR Mono | Add-on Quetiapine XR | Add-on Lithium |
|---|---|---|---|
| Change in Sleep Quality Measured by Pittsburgh Sleep Quality Index (PSQI) | -4.77 ± 0.36 | -4.96 ± 0.358 | -3.51 ± 0.364 |
Self rating assessment of quality in life using SF-36, mental component (Scale 0-100, where a higher value shows a larger improvement)
| Scores on a scale | Quetiapine XR Mono | Add-on Quetiapine XR | Add-on Lithium |
|---|---|---|---|
| Change in Quality of Life Measured by Short-form Health Survey (SF-36), Mental Component | 9.59 ± 0.929 | 10.77 ± 0.925 | 9.66 ± 0.932 |
Self rating assessment of quality in life using SF-36, physical component (Scale 0-100, where a higher value shows a larger improvement)
| Scores on a scale | Quetiapine XR Mono | Add-on Quetiapine XR | Add-on Lithium |
|---|---|---|---|
| Change in Quality of Life Measured by Short-form Health Survey (SF-36), Physical Component | 5.224 ± 0.811 | 5.065 ± 0.813 | 4.566 ± 0.817 |
Self rating assessment of quality in life using EQ-5D utility (Scale 0-100, where a higher value shows a larger improvement)
| Scores on a scale | Quetiapine XR Mono | Add-on Quetiapine XR | Add-on Lithium |
|---|---|---|---|
| Change in Quality of Life Measured by Health Questionnaire EQ-5D as Utility | 0.184 ± 0.023 | 0.224 ± 0.023 | 0.208 ± 0.023 |
Self rating assessment of working productivity using WPAI:GH (Scale 0 to number of hours worked during a week multiplied with the salary in Euro, a lower value shows a larger improvement)
| Scores on a scale | Quetiapine XR Mono | Add-on Quetiapine XR | Add-on Lithium |
|---|---|---|---|
| Change in Work Productivity and Activity Impairment: General Health (WPAI:GH) | -233 ± 0.023 | -185 ± 0.023 | -299 ± 0.023 |
The physician has evaluated the therapeutic effect and the side effect combined at end of study. Patients with a 'marked/moderate' therapeutic effect and 'None/Do Not Significantly Interfere' side effect has been added. The higher values show more patients with a treatment effect without any side-effect. The range is from 0 patients to the maximum number of patients in the treatment arm (225, 229 or 221).
| Participants | Quetiapine XR Mono | Add-on Quetiapine XR | Add-on Lithium |
|---|---|---|---|
| Change in Clinical Global Impression (CGI) Item 4 Efficacy and Safety Combined, All Patients | 135 | 146 | 131 |
The physician has evaluated the therapeutic effect and the side effect combined at end of study. Patients with a 'marked/moderate' therapeutic effect and 'None/Do Not Significantly Interfere' side effect has been added. The higher values show more patients with a treatment effect without any side-effect. The range is from 0 patients to the maximum number of patients in the treatment arm.
| Participants | Quetiapine XR Mono | Add-on Quetiapine XR | Add-on Lithium |
|---|---|---|---|
| Change in Clinical Global Impression (CGI) Item 4 Efficacy and Safety Combined, Patients With One Previous Treatment Failure | 67 | 75 | 69 |
The physician has evaluated the therapeutic effect and the side effect combined at end of study. Patients with a 'marked/moderate' therapeutic effect and 'None/Do Not Significantly Interfere' side effect has been added. The higher values show more patients with a treatment effect without any side-effect. The range is from 0 patients to the maximum number of patients in the treatment arm.
| Participants | Quetiapine XR Mono | Add-on Quetiapine XR | Add-on Lithium |
|---|---|---|---|
| Change in Clinical Global Impression (CGI) Item 4 Efficacy and Safety Combined, Patients With Two Previous Treatment Failures | 68 | 71 | 62 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Quetiapine XR Mono | — | 5/228 (2.2%) | 93/228 (40.8%) |
| Add-on Quetiapine XR | — | 5/231 (2.2%) | 90/231 (39%) |
| Add-on Lithium | — | 2/229 (0.9%) | 41/229 (17.9%) |
| Event | Quetiapine XR Mono | Add-on Quetiapine XR | Add-on Lithium |
|---|---|---|---|
| DepressionPsychiatric disorders | 0/228 | 3/231 | 1/229 |
| Affective DisorderPsychiatric disorders | 1/228 | 0/231 | 0/229 |
| Psychotic DisorderPsychiatric disorders | 1/228 | 0/231 | 0/229 |
| RestlessnessPsychiatric disorders | 1/228 | 0/231 | 0/229 |
| Suicidal IdeationPsychiatric disorders | 1/228 | 0/231 | 0/229 |
| OverdoseInjury, poisoning and procedural complications | 1/228 | 0/231 | 0/229 |
| CholelithiasisHepatobiliary disorders | 0/228 | 0/231 | 1/229 |
| DiarrhoeaGastrointestinal disorders | 0/228 | 1/231 | 0/229 |
| ManiaPsychiatric disorders | 0/228 | 1/231 | 0/229 |
| Event | Quetiapine XR Mono | Add-on Quetiapine XR | Add-on Lithium |
|---|---|---|---|
| SomnolenceNervous system disorders | 22/228 | 20/231 | 0/229 |
| Dry mouthGastrointestinal disorders | 13/228 | 22/231 | 6/229 |
| FatigueGeneral disorders | 21/228 | 13/231 | 7/229 |
| SedationNervous system disorders | 15/228 | 11/231 | 0/229 |
| TremorNervous system disorders | 0/228 | 0/231 | 15/229 |
| DizzinessNervous system disorders | 11/228 | 14/231 | 0/229 |
| HeadacheNervous system disorders | 11/228 | 10/231 | 13/229 |
| Age Continuous(years) | Quetiapine XR Mono | Add-on Quetiapine XR | Add-on Lithium | Total |
|---|---|---|---|---|
| Mean | 47 (20 to 65) | 47 (20 to 67) | 47 (19 to 67) | 47 (19 to 67) |
| Sex: Female, Male(Participants) | Quetiapine XR Mono | Add-on Quetiapine XR | Add-on Lithium | Total |
|---|---|---|---|---|
| Female | 152 | 162 | 152 | 466 |
| Male | 73 | 67 | 69 | 209 |
| Diagnostic and Statistical Manual of Mental Disorders (DSM-IV)(Participants) | Quetiapine XR Mono | Add-on Quetiapine XR | Add-on Lithium | Total |
|---|---|---|---|---|
| Diagnose code 296.2x Major Depressive Disorder (MD | 50 | 36 | 41 | 127 |
| Diagnose code 296.3x MDD, Recurrent | 175 | 193 | 180 | 548 |
| Montgomery-Asberg Depression Rating Scale (MADRS) total score(Units on a scale) | Quetiapine XR Mono | Add-on Quetiapine XR | Add-on Lithium | Total |
|---|---|---|---|---|
| Mean | 33.74 ± 5.6 | 33.15 ± 5.34 | 32.91 ± 5.2 | 33.32 ± 5.4 |
| Weight(kg) | Quetiapine XR Mono | Add-on Quetiapine XR | Add-on Lithium | Total |
|---|---|---|---|---|
| Mean | 75.3 ± 17.2 | 75.2 ± 17 | 76.4 ± 16.1 | 75.8 ± 16.65 |
Showing the first 100 of 106 sites across 13 countries. Choose a country and city above to see the rest.
The record gives a start of Nov 2008, a primary completion of Aug 2009 and a completion of Aug 2009. It does not say whether these dates are actual or estimated.
Results were first posted in May 2012, 2 years 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Quetiapine · Lithium Carbonate · Venlafaxine